PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOUR CONTAINING FUSED PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN, AND ANTICANCER AGENT Russian patent published in 2025 - IPC A61K38/00 A61K38/20 A61K31/00 A61P35/00 

Abstract RU 2839599 C1

FIELD: pharmaceutics.

SUBSTANCE: present invention relates to a pharmaceutical composition for preventing or treating a malignant tumour, containing, as active ingredients, a dimeric fusion protein containing a CD80 fragment and an IL-2 variant, and an anticancer agent; wherein the fused protein has the following structural formula (I): N'-X-[linker (1)]n-Fc-domain-[linker (2)]m-Y-C' (I), where N' is the N-end of the fused protein, C' is the C-end of the fused protein, X is a CD80 fragment, wherein the CD80 fragment is an extracellular domain of the CD80 protein, Y is a variant of the IL-2 protein containing substitutions R38A and F42A in the amino acid sequence SEQ ID NO: 10, linker (1) is a peptide linker consisting of the amino acid sequence SEQ ID NO: 3, linker (2) is a peptide linker consisting of the amino acid sequence SEQ ID NO: 5, and n and m are equal to 1, and wherein the anticancer agent is any selected from the group consisting of: VEGFR inhibitor, EGFR inhibitor, PARP inhibitor, DNA methyltransferase inhibitor, TGF-β receptor inhibitor, CDK4/6 inhibitor, STING agonist, alkylating agent, microtubule inhibitor, antimetabolite, topoisomerase inhibitor and combinations thereof.

EFFECT: present invention provides the development of the most effective structure of the fused protein, which stimulates the proliferation of CD80+ T- and NK-cells without increasing the number of Treg-cells, as well as an optimum distance allowing two active domains in the fused protein to work synergistically without steric interference in binding to each target, wherein the obtained structure interacts effectively with all CTLA-4 on regulatory T cells; IL2Rβ on NK cells; and IL2Rβ on effector T cells, thus showing an unexpected synergistic anticancer effect in animal models compared to single or combined treatment with each protein as a separate molecule.

11 cl, 29 tbl, 133 dwg, 49 ex

Similar patents RU2839599C1

Title Year Author Number
PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOUR CONTAINING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN, AND IMMUNE CONTROL POINT INHIBITOR 2020
  • Jang, Myoung Ho
  • Nam, Su Youn
  • Koh, Young Jun
  • Cho, Young-Gyu
RU2828377C1
FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE 2019
  • Jang, Myung Ho
RU2811541C2
COMPOSITION FOR ANTICANCER TREATMENT CONTAINING NK-CELLS AND FUSION PROTEIN WHICH CONTAINS IL-2 PROTEIN AND CD80 PROTEIN 2020
  • Chan, Meun Kho
  • Khon, Chkhon-Pe
  • Yan, Tszun Eon
  • Kokh, Eun Dzhun
  • Li, Dzhun Sub
  • Chkhoi, Eun Dzhoo
RU2832136C1
FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF 2021
  • Kim, Donggeon
  • Ryu, Soomin
  • Lee, Dahea
  • Kim, Dongsu
  • Chang, Jihoon
  • Lee, Byoung Chul
RU2831612C1
FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE 2018
  • Gu, Tszinmin
  • Lo, Syao
  • Tao, Vejkan
RU2776204C1
FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS 2018
  • Sini, Dzhon, K.
  • Khuan, Khaomin
RU2786444C2
BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 2019
  • Kluge Michael
  • Tesar Michael
  • Fucek Ivica
  • Ellwanger Kristina
  • Reusch Uwe
  • Damrat Michael
  • Rajkovic Erich
  • Treder Martin
RU2792240C2
BISPECIFIC FUSION PROTEIN AND ITS USE 2021
  • Fang, Jianmin
RU2801528C2
FUSION PROTEIN CONTAINING HUMAN LEFTY A PROTEIN VARIANTS AND ITS USE 2019
  • Chon, Sun-Yun
  • Li, Kyun U
  • Mun, Son Ke
  • Kan, Sun Chon
  • Chkhve, Pen-Ok
  • Kvak, Chon
  • Chan, Chon Uk
  • Kim, Chon Khen
RU2793631C2
FUNCTION PROTEIN AND ITS USE 2019
  • Lv, Ming
  • Ding, Xiaoran
  • Miao, Shiwei
  • Tan, Bin
  • Wang, Xuegong
RU2800923C2

RU 2 839 599 C1

Authors

Jang, Myung Ho

Nam, Su Youn

Koh, Young Jun

Dates

2025-05-06Published

2021-03-18Filed